Cargando…

Targeting immunotherapy for bladder cancer using anti‐CD3× B7‐H3 bispecific antibody

OBJECTIVE: B7‐H3 is attractive for cancer immunotherapy with B7‐H3 overexpressed tumors. To explore whether B7‐H3 is an effective target for patients with bladder cancer, anti‐CD3× anti‐B7‐H3 bispecific antibodies (B7‐H3Bi‐Ab) was armed with activated T cells (ATC) to kill bladder cancer cells. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Wanru, Ma, Juan, Ma, Ping, Lei, Ting, Zhao, Man, Zhang, Man
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198238/ https://www.ncbi.nlm.nih.gov/pubmed/30253078 http://dx.doi.org/10.1002/cam4.1775

Ejemplares similares

Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody
por: Ma, Wanru, et al.
Publicado: (2019)

A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity
por: Feng, Yan, et al.
Publicado: (2022)

Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies
por: Kerns, S Jordan, et al.
Publicado: (2021)

Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
por: van Diest, Eline, et al.
Publicado: (2021)

In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
por: Kruse, Robert L., et al.
Publicado: (2017)

B7‐H3 protein expression in acute myeloid leukemia
por: Guery, Thomas, et al.
Publicado: (2015)

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
por: Dang, Kevin, et al.
Publicado: (2021)

Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer
por: Wang, Yejinpeng, et al.
Publicado: (2020)

Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications
por: Compte, Marta, et al.
Publicado: (2014)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
por: Mehta, Naveen K, et al.
Publicado: (2022)

Vitamin D(3) enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk
por: Bunch, Brittany L., et al.
Publicado: (2019)

A novel monoclonal antibody KMP1 has potential antitumor activity of bladder cancer by blocking CD44 in vivo and in vitro
por: Chen, Yujin, et al.
Publicado: (2018)

Blockade of CD82 by a monoclonal antibody potentiates anti-leukemia effects of AraC in vivo
por: Nishioka, Chie, et al.
Publicado: (2015)

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
por: Guancial, Elizabeth A, et al.
Publicado: (2014)

Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate
por: Waaijer, Stijn JH, et al.
Publicado: (2020)

Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy
por: Groeneveldt, Christianne, et al.
Publicado: (2020)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
por: Yang, Yan, et al.
Publicado: (2021)

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
por: Lutz, Martina S., et al.
Publicado: (2023)

Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus
por: Tang, Jing, et al.
Publicado: (2022)

Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones
por: Sarthy, Jay F, et al.
Publicado: (2020)

Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
por: Blanco, Belén, et al.
Publicado: (2021)

Suppression of MUC1-Overexpressing Tumors by a Novel MUC1/CD3 Bispecific Antibody
por: Fang, Jun, et al.
Publicado: (2023)

Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others
por: Kobayashi, Hideaki, et al.
Publicado: (2013)

A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies
por: Ferl, Gregory Z., et al.
Publicado: (2018)

Development of a reporter gene method to measure the bioactivity of anti-CD38 × CD3 bispecific antibody
por: Xiong, Hui, et al.
Publicado: (2021)

Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity
por: Faber, Mary L., et al.
Publicado: (2023)

MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody
por: Li, Hongjian, et al.
Publicado: (2020)

Global research trends on B7-H3 for cancer immunotherapy: A bibliometric analysis (2012-2022)
por: Huang, Xiaojuan, et al.
Publicado: (2023)

Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early‐stage breast cancer patients treated with anthracycline‐based adjuvant chemotherapy
por: Tsiatas, Marinos, et al.
Publicado: (2018)

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy
por: Santich, Brian H., et al.
Publicado: (2020)

Bispecific antibodies come to the aid of cancer immunotherapy
por: Amelio, Ivano, et al.
Publicado: (2021)

A NOVEL B7H3/NKP30 BISPECIFIC NK CELL ENGAGER FOR CANCER IMMUNOTHERAPY
por: Jiang, Xiaoling, et al.
Publicado: (2023)

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
por: Middelburg, Jim, et al.
Publicado: (2021)

CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis
por: Li, Fangxuan, et al.
Publicado: (2019)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
por: Huan, Tian, et al.
Publicado: (2023)

Association of human breast cancer CD44(-)/CD24(-) cells with delayed distant metastasis
por: Qiao, Xinbo, et al.
Publicado: (2021)

Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
por: Pan, Haitao, et al.
Publicado: (2018)

Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo
por: Zhong, Liping, et al.
Publicado: (2021)

The CD73 immune checkpoint promotes tumor cell metabolic fitness
por: Allard, David, et al.
Publicado: (2023)

GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome
por: Zhou, Jing‐Dong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8d05hn8dg6vg5s203g4janpcdj